drugset
drugset / Trial / NCT03811678

The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects

NCT03811678 ↗

Phase 1 Completed 120 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects.

Timeline

Start
2018-01-11
Primary completion
2018-05-29
Completion
2018-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Kangdaprevir Unknown 50 mg Oral
Subject Kangdaprevir Unknown 100 mg Oral
Subject Kangdaprevir Unknown 200 mg Oral
Subject Kangdaprevir Unknown 400 mg Oral
Subject Kangdaprevir Unknown 600 mg Oral
Subject Kangdaprevir Unknown 800 mg Oral

Indications

chronic hepatitis C virus infection